Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;28(36):49343-49361.
doi: 10.1007/s11356-021-15623-6. Epub 2021 Jul 28.

Microbiota and epigenetics: promising therapeutic approaches?

Affiliations
Review

Microbiota and epigenetics: promising therapeutic approaches?

Amr El-Sayed et al. Environ Sci Pollut Res Int. 2021 Sep.

Abstract

The direct/indirect responsibility of the gut microbiome in disease induction in and outside the digestive tract is well studied. These results are usually from the overpopulation of certain species on the cost of others, interaction with beneficial microflora, interference with normal epigenetic control mechanisms, or suppression of the immune system. Consequently, it is theoretically possible to cure such disorders by rebalancing the microbiome inside our bodies. This can be achieved by changing the lifestyle pattern and diet or by supplementation with beneficial bacteria or their metabolites. Various approaches have been explored to manipulate the normal microbial inhabitants, including nutraceutical, supplementations with prebiotics, probiotics, postbiotics, synbiotics, and antibiotics, or through microbiome transplantation (fecal, skin, or vaginal microbiome transplantation). In the present review, the interaction between the microbiome and epigenetics and their role in disease induction is discussed. Possible future therapeutic approaches via the reestablishment of equilibrium in our internal micro-ecosystem are also highlighted.

Keywords: Epigenetic; FMT; Fecal microbiota transplantation; Microbiome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Similar articles

Cited by

References

    1. Alang N, Kelly CR (2015) Weight gain after fecal microbiota transplantation, Open forum infectious diseases. Oxford University Press 2(1) - PMC - PubMed
    1. Al-Ghazzewi F, Tester R. Biotherapeutic agents and vaginal health. J Appl Microbiol. 2016;121:18–27. doi: 10.1111/jam.13054. - DOI - PubMed
    1. Amato RJ. Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clin Genitourin Cancer. 2007;5:422–426. doi: 10.3816/CGC.2007.n.029. - DOI - PubMed
    1. Ambrose N, Allan R, Keighley M, Burdon D, Youngs D, Barnes P, Lennard-Jones J. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. Dis Colon Rectum. 1985;28:81–85. doi: 10.1007/BF02552649. - DOI - PubMed
    1. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, Novacek G, Trauner M, Loy A, Berry D. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013;108:1620. doi: 10.1038/ajg.2013.257. - DOI - PubMed

LinkOut - more resources